Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Ensysce Biosciences stock | $13.85

Learn how to easily invest in Ensysce Biosciences stock.

Ensysce Biosciences Inc is a shell companies business based in the US. Ensysce Biosciences shares (LACQ) are listed on the PINK and all prices are listed in US Dollars.

How to buy shares in Ensysce Biosciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LACQ – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Ensysce Biosciences stock price (PINK: LACQ)

Use our graph to track the performance of LACQ stocks over time.

Ensysce Biosciences shares at a glance

Information last updated 2021-07-31.
Latest market close$13.85
52-week range$10.47 - $21.80
50-day moving average $13.97
200-day moving average $13.65
Wall St. target priceN/A
PE ratio 118.7705
Dividend yield N/A (0%)
Earnings per share (TTM) $0.12

Buy Ensysce Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Ensysce Biosciences price performance over time

Historical closes compared with the close of $13.85 from 2021-05-28

1 week (2021-10-12) N/A
1 month (2021-09-19) N/A
3 months (2021-07-19) N/A
6 months (2021-04-23) 8.88%
1 year (2020-10-23) 28.84%
2 years (2019-10-23) 35.12%
3 years (2018-10-23) 42.34%
5 years (2016-10-19) N/A

Is Ensysce Biosciences under- or over-valued?

Valuing Ensysce Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ensysce Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ensysce Biosciences's P/E ratio

Ensysce Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 119x. In other words, Ensysce Biosciences shares trade at around 119x recent earnings.

Ensysce Biosciences financials

Gross profit TTM $0
Return on assets TTM -1.25%
Return on equity TTM 23.4%
Profit margin 0%
Book value $0.30
Market capitalisation $90.2 million

TTM: trailing 12 months

Shorting Ensysce Biosciences shares

There are currently 2,958 Ensysce Biosciences shares held short by investors – that's known as Ensysce Biosciences's "short interest". This figure is 21% up from 2,445 last month.

There are a few different ways that this level of interest in shorting Ensysce Biosciences shares can be evaluated.

Ensysce Biosciences's "short interest ratio" (SIR)

Ensysce Biosciences's "short interest ratio" (SIR) is the quantity of Ensysce Biosciences shares currently shorted divided by the average quantity of Ensysce Biosciences shares traded daily (recently around 2310.9375). Ensysce Biosciences's SIR currently stands at 1.28. In other words for every 100,000 Ensysce Biosciences shares traded daily on the market, roughly 1280 shares are currently held short.

However Ensysce Biosciences's short interest can also be evaluated against the total number of Ensysce Biosciences shares, or, against the total number of tradable Ensysce Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ensysce Biosciences's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Ensysce Biosciences shares in existence, roughly 0 shares are currently held short) or 0.0021% of the tradable shares (for every 100,000 tradable Ensysce Biosciences shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ensysce Biosciences.

Find out more about how you can short Ensysce Biosciences stock.

Ensysce Biosciences share dividends

We're not expecting Ensysce Biosciences to pay a dividend over the next 12 months.

Ensysce Biosciences share price volatility

Over the last 12 months, Ensysce Biosciences's shares have ranged in value from as little as $10.47 up to $21.8. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Ensysce Biosciences's is -0.1134. This would suggest that Ensysce Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Ensysce Biosciences has bucked the trend.

Ensysce Biosciences overview

Ensysce Biosciences, Inc. operates as a biotechnology company that develops abuse-resistant drug technologies. It offers TAAP, a trypsin-activated abuse protection technology that prevents abuse through a two-step internal trypsin-activation process to meet the medical needs of patients living with chronic pain; and MPAR, a multi-pill abuse resistant technology that provides a layer of protection for overdose. The company was incorporated in 2003 and is based in La Jolla, California. .

Ensysce Biosciences in the news

There are no recent company news

Frequently asked questions

What percentage of Ensysce Biosciences is owned by insiders or institutions?
Currently 39.841% of Ensysce Biosciences shares are held by insiders and 56.672% by institutions.
When does the fiscal year end for Ensysce Biosciences?
Ensysce Biosciences's fiscal year ends in December.
Where is Ensysce Biosciences based?
Ensysce Biosciences's address is: 7946 IVANHOE AVENUE, La Jolla, CA, United States, 92037
What is Ensysce Biosciences's ISIN number?
Ensysce Biosciences's international securities identification number is: US2936021086
What is Ensysce Biosciences's CUSIP number?
Ensysce Biosciences's Committee on Uniform Securities Identification Procedures number is: 52539T107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site